ASCO publishes a suite of peer-reviewed journals with content focused on

  • clinical oncology research;
  • issues and insights affecting oncology practice;
  • cancer care, research, and care delivery issues unique to countries and settings with limited health care resources;
  • biomedical informatics methods and processes applied to cancer-related data, information, and images; and
  • the science and practice of precision oncology.

ASCO’s peer-reviewed journals follow a continuous publication schedule. Below is a select list of the newest content from ASCO’s journals. ASCO will update the list on a near-daily basis, and we encourage you to check this page frequently. Email ASCO’s Media Team to request an embargoed journal article or an interview with a study author.

ASCO occasionally highlights select journal articles in an embargoed press release known as a News Digest or in a Featured Article summary. Sign up to receive communications regarding these articles.

Publishing December 6, 2022, 4:00 PM ET:

Integrating tobacco treatment into oncology care: Reach and effectiveness of evidence-based tobacco treatment across NCI-Designated Cancer Centers (Original Report)
Sarah D. Hohl, et al.
Request article

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: Final Results of CheckMate 651 (Original Report)
Robert I. Haddad, et al.
Request article

Clinical benefit of first-line PD-1 antibody plus chemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma: A post-hoc analysis of JUPITER-06 and meta-analysis (Original Report)
Feng Wang, et al.
Request article

Impact of Geriatric Assessment and Management on quality of life, unplanned hospitalizations, toxicity, and survival for older adults with cancer: the randomized 5C trial (Original Report)
Martine Puts, et al.
Request article

Publishing December 5, 2022, 4:00 PM ET:

Multicenter Phase 2 Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification (Original Report)
Siqing Fu, et al.
Request article

Symptom Clusters in Childhood Cancer Survivors (Editorial)
Smita Bhatia, et al.
Request article

Published December 2, 2022, 4:00 PM ET:

Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study (Original Report)
Carrie Kitko, et al.
Request article

Learning about mismatch repair from a rare cancer syndrome: a LOGICal step forward (Editorial)
Junne Kamihara, et al.
Request article

Published December 1, 2022, 4:00 PM ET:

Financial Burden in Blood or Marrow Transplantation Survivors during the COVID-19 Pandemic: A BMTSS Report (Original Report)
Smita Bhatia, et al.
Request article

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial (Original Report)
Mina S. Sedrak, et al.
Request article

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients from Asia with Advanced Hepatocellular Carcinoma: A Randomized, Double-blind, Phase III Trial (Original Report)
Shukui Qin, et al.
Request article

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer (Original Report)
Jinani Jayasekera, et al.
Request article

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase 3 Trial within the EMSCO network (Original Report)
Raphael Itzykson, et al.
Request article

Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype (Original Report)
Camryn Cohen, et al.
Request article

Exploring the Role of the Inhibitor of Apoptosis BIRC6 in Breast Cancer: A Database Analysis (Original Report)
Matias Pidre, et al.
Request article

Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study (Original Report)
Chanchai Charonpongsuntorn, et al.
Request article 

Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database (Original Report)
Yusuke Kajimoto, et al.
Request article 

Published November 30, 2022, 4:00 PM ET:

Risk stratification of non-muscle invasive bladder cancer and innovative approaches to management of small Ta tumors (Editorial)
Seth Lerner, et al.
Request article

Published November 29, 2022, 4:00 PM ET:

Antibody Drug Conjugates in Breast Cancer: Searching for Magic Bullets (Editorial)
Antonio Wolff, et al.
Request article

The PRINCIPAL Network: A Model to Optimize Infection Care and Prevention in Pediatric Oncology in the Latin American Region (Special Article)
Miguela Caniza, et al.
Request article

Rare FGFR oncogenic alterations in sequenced pediatric solid and brain tumors suggest FGFR is a relevant molecular target in childhood cancer (Original Report)
Suzanne J. Forrest, et al.
Request article

Implementation of the TiTE-CRM design in a phase I platform trial testing novel radiotherapy-drug combinations – CONCORDE (Original Report)
Sarah R. Brown, et al.
Request article

Germline Variants in DNA Damage Repair Genes and HOXB13 among Black Patients with Early-Onset Prostate Cancer (Original Report)
Jennifer Lynn Beebe-Dimmer, et al.
Request article

Comparison of PIK3CA mutation prevalence in breast cancer across predicted ancestry populations (Original Report)
Katherine E Hutchinson, et al.
Request article

Proceedings from the American Society of Clinical Oncology/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit (Special Article)
Daniel F. Hayes, et al.
Request article


The embargo date and time of a journal article coincide with its online publication date and time. Journalists may conduct embargoed interviews with study authors up to one week prior to the online publication date. ASCO takes embargo violations seriously and violations typically result in the loss of journal media privileges for a period of one year and may affect broader ASCO media privileges as well. Journalists may request embargoed articles. Please direct further questions regarding the embargo policies for ASCO Journals to the Media Team.